paolo_paoletti

Former GSK Oncology president joins Kesios

pharmafile | June 1, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Paolo Paoletti, kesios 

The Imperial Innovations Group has confirmed the appointment of Dr Paolo Paoletti to be the executive chairman of Kesios Therapeutics.

Paoletti was formerly the first appointed president of GSK Oncology, where as the leader of its business unit he was responsible for the overall oncology portfolio within GlaxoSmithKline – from early drug discovery through clinical development, launch and life cycle management. 

Paoletti is also non-executive director of PsiOxus Therapeutics, Innovation’s sixth largest portfolio company, which is developing innovative oncolytic immuno-oncology treatments for cancer.
 
UK-based Kesios, which is in the Imperial incubator in South Kensington, was created to develop and commercialise certain research from the Department of Medicine at Imperial College London.

Advertisement

Paoletti says: “I’m extremely pleased to take this role to accelerate the clinical development of this new molecule and, hopefully, to translate the very innovative and interesting pre-clinical science in an impactful medicine for patients affected by Multiple Myeloma and other forms of cancer.”

Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

Multiple myeloma treatment approved in Japan

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …

The Gateway to Local Adoption Series

Latest content